Expert Insight |Dr. Zhengsheng Zou: Advances in the Diagnosis and Treatment of Drug-Induced Liver Failure

2024.03.15
Drug-induced liver injury (DILI) is a significant adverse reaction to medications, with severe cases leading to acute liver failure (ALF) and even death. DILI is the most common cause of ALF in Western countries, yet there is still a lack of simple, specific diagnostic indicators and effective treatment methods. The incidence of DILI in China is increasing year by year, related to the variety of clinical drugs, improper medication use, and insufficient awareness. During the recent closure of the 10th "Huaxia Shanghai Liver Disease Forum and Forum on the Diagnosis and Treatment of Liver Failure and its Complications," Dr. Zhengsheng Zou from the Fifth Medical Center of the PLA General Hospital shared insights into the progress of the diagnosis and treatment of drug-induced liver failure, covering its importance, etiology, pathogenic mechanisms, clinical manifestations, treatment strategies, prognosis assessment, and large-scale studies in China.
Highlights of the Annual Conference | Dr. Jie Li: Comorbidity and Management of Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) in the New Era

Highlights of the Annual Conference | Dr. Jie Li: Comorbidity and Management of Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) in the New Era

2024.03.14
The 21st National Conference on Viral Hepatitis and Hepatology, and the Annual Meetings of the Chinese Society of Hepatology and the Chinese Society of Infectious Diseases, took place from December 22nd to 24th, 2023, in Chengdu, Sichuan Province. This conference, co-hosted by the Chinese Medical Association, the Chinese Society of Hepatology, and the Chinese Society of Infectious Diseases, and organized by the Sichuan Medical Association, showcased the latest developments and hot topics in the research of viral hepatitis, hepatology, and infectious diseases. During the event, Dr. Jie Li from Nanjing University Medical School's Drum Tower Hospital shared insights on the comorbidity and management of diabetes and non-alcoholic fatty liver disease (NAFLD). The following is a summary of her presentation.

Expert Insight | Dr. XiaoheXiao: Precision Medication – Making Traditional Chinese Medicine the Guardian of the Body’s “Chemical Factory”

2024.03.14
The liver, as the "chemical factory" of the human body, is responsible for the synthesis and metabolism of various crucial substances, while also serving as the "detoxification center" for harmful waste and toxins. However, the liver faces numerous challenges, including external factors such as viruses, bacteria, alcohol, drugs, and internal factors like self-consumption, immune imbalance, acute and chronic liver diseases, which can disrupt the liver's tissue structure and functioning. Traditional Chinese Medicine (TCM) has rich applications in safeguarding the liver. Still, issues related to liver damage caused by Chinese herbal medicine have sparked debates about whether TCM is a "toxin" or a "guardian" for the liver. In a recent report at the 10th "Huaxia Shanghai Liver Disease Forum and Advances in Diagnosis and Treatment of Liver Failure and Its Complications Forum," Dr. Xiaohe Xiao from the Fifth Medical Center of the PLA General Hospital discussed the overall situation of the safety of Chinese herbal medicine and explored practical solutions.

Expert’s Insight | Dr. Chenghai Liu: ” Dual Antagonism” Strategy Assists in the Full Course Management of Chronic Liver Disease

2024.03.13
Improving the prognosis of chronic viral hepatitis is a crucial goal in clinical treatment. Chronic hepatitis B (CHB) has a wide incidence, and its severe harm mainly stems from the progression from liver fibrosis to cirrhosis, leading to decompensated cirrhosis and liver cancer, seriously threatening the patient's life and health. Therefore, reversing early cirrhosis is of significant importance for reducing the risk of CHB-related liver diseases and death, representing an essential clinical need in CHB treatment. However, antiviral therapy alone has certain limitations, and traditional Chinese medicine (TCM) has enormous potential in combating liver fibrosis. At the recent 10th "Huaxia Shanghai Liver Disease Forum and Progress in Diagnosis and Treatment of Liver Failure and Its Complications," Dr. Chenghai Liu from the Liver Disease Research Institute of Shanghai Academy of Traditional Chinese Medicine, and the Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine shared the significant clinical benefits that the "dual antagonism" prevention and treatment strategy, combining antiviral therapy with TCM for anti-liver fibrosis, brings to CHB patients. The content has been compiled into an article for readers.

Interpretation of “Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma”

2024.01.12
On December 9-10, 2023, the "Huaxia Shanghai Liver Disease Forum and Shanghai Liver Disease Summit" was successfully held, sponsored by the Huaxia Liver Disease Association, organized by the Shanghai "Liver" Magazine, and co-organized by the Shanghai Medical Association Hepatology Subspecialty Branch, Shanghai Physicians Association Infectious Disease Physicians Branch, Shanghai Infectious Disease Clinical Quality Control Center, and the Long Triangle Representative Office of the China Association of Non-Public Medical Institutions. At the conference, Dr.Xiufeng Liu from the Medical Area of the Qinhuai Hospital of the Eastern Theater General Hospital of the People's Liberation Army provided a detailed interpretation of the "Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma," which was newly issued in China. This journal has invited Dr.Xiufeng Liu to conduct an in-depth interview to introduce the consensus's recommendations regarding first-line and subsequent-line treatment options for liver cancer immunotherapy, as well as the assessment of treatment efficacy and other hot topics. The following content summarizes these insights for readers.